Payers want pharma to address the challenges they face
Specialised cancer therapies such as checkpoint inhibitors have significantly improved outcomes for patients—but for payers they represent a growing pricing and reimbursement (P&R) challenge, especially as triple and quadruple oncology therapy becomes more commonplace. To achieve formulary position and the widest possible prescribing, pharma needs payers positively on board, so what practical steps can developers take to get payer support for their oncology product’s pricing and reimbursement ambitions?
Understanding the pressures and touchpoints that resonate with payers is critical. That is why, in February 2020, we interviewed 8 experienced US and European payers in Pricing and Reimbursement in Oncology: Payer Views to reveal their attitudes and needs and the practical steps pharma can take to address their concerns.
Payers explore key questions such as…
- Why are payers cautious about progression-free survival as a clinical endpoint and what clinically meaningful metrics could be used for P&R assessment?
- What real-world evidence is valuable to payers when making P&R decisions and what comprises a trusted source of such data?
- In what circumstances do payers see value-based contracting having a place in oncology?
- Companion diagnostics can play a critical role in identifying responsive patients: should payers carry the cost of their use?
- Are drug price controls the way forward in the US to tackle the growing cost burden of oncology medicines?
- What are the key challenges that payers face when funding costly one-time treatments, such as CAR-T cell therapies?